Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC

Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration

Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal

Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology

Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies

Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)

Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD

Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal

Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL

Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership

Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH

Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH Professional audiences…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax

Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…


Privacy Preference Center